Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Metastatic Urothelial Bladder Cancer (Companion Faculty Lecture)
Research To Practice | Oncology Videos · Dr. Neil Love
August 30, 202443m 59s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics:
- Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00)
- Principal findings from the Phase III CheckMate 901 substudy of nivolumab in combination with chemotherapy and continued as monotherapy compared to chemotherapy alone as first-line treatment for cisplatin-eligible patients with mUBC (14:36)
- Key data from the Phase III THOR trial of erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations (22:03)
- Long-term findings with sacituzumab govitecan for patients with progressive mUBC; emerging data from the Phase III TROPiCS-04 study (29:43)
- Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (36:19)